PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2017-09-01
|
Series: | Radiology and Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1515/raon-2017-0037 |
Summary: | With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression in tumor cells (TC) and immune cells (IC) of squamous-cell carcinoma (SCC) and adenocarcinoma (AC) patients. |
---|---|
ISSN: | 1581-3207 |